EGFR and non-small cell lung carcinoma: Though most adjuvant therapy is now with cisplatin-based doublet chemotherapy combinations, third-generation EGFR inhibitor, osimertinib, was recently shown to dramatically improve disease-free survival in patients with resectable EGFR-mutant NSCLC.